Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lina Fu

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Nature Communications|June 20, 2025
Author Correction: PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotypeShunlei Duan, Guohong Yuan, Xiaomeng Liu, et al.
Annals of Hematology|June 18, 2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINEKeshu Zhou, Tingyu Wang, Ling Pan, et al.
Nature Communications|December 4, 2015
PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotypeShunlei Duan, Guohong Yuan, Xiaomeng Liu, et al.
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Future Oncology (London, England)|August 12, 2024
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Nature Communications|June 20, 2025
Author Correction: PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotypeShunlei Duan, Guohong Yuan, Xiaomeng Liu, et al.
Annals of Hematology|June 18, 2024
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINEKeshu Zhou, Tingyu Wang, Ling Pan, et al.
Nature Communications|December 4, 2015
PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotypeShunlei Duan, Guohong Yuan, Xiaomeng Liu, et al.
Future Oncology (London, England)|December 13, 2023
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Future Oncology (London, England)|August 12, 2024
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatmentJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.
Pageof 8